All Issues
Year: 2014  Vol. 18   Num. 1  - Jan/Mar
DOI: 10.1055/s-0033-1358579
Original Article
Versão em PDF PDF in English TextoText in English
Newborn Hearing Screening in Neonates Exposed to Psychoactive Drugs
Bruna Salazar Castro da Rocha, Mrcia Salgado Machado, Cludia Fernandes Costa Zanini, Tatiana de Carvalho Paniz, Isabela Hoffmeister Menegotto
Key words:
newborn screening - psychotropic drugs - hearing

Introduction: In pregnancy, the mother and fetus share body structures based on the maternal organism. Exposure to psychoactive drugs in this period may have repercussions on the baby's hearing. Therefore, it is necessary to investigate this association.

Aim: Analyze the results of newborn hearing screening (NHS), the occurrence of associated risk factors, and the incidence of hearing loss in newborn exposed to psychoactive drugs during pregnancy.

Methods: This is an observational retrospective study done from a database analysis. From this database, records were selected about the use of psychoactive drugs by mothers during pregnancy, then the neonates were divide into two groups: the study group (146 babies exposed to drugs) and the control group (500 babies not exposed to drugs). The NHS failure rate, the presence of risk factors for hearing loss, and need for audiological diagnosis were analyzed in both groups. From these variables, absolute frequency and prevalence rates were calculated and the results compared between groups.

Results: There was no statistically significant difference in the comparison of NHS failure rates between the groups (p = 0.267). The occurrence of risk factors for hearing loss was greater in babies exposed to drugs (p < 0.0001). There was only one diagnosis of hearing loss, which occurred in the control group (p = 0.667).

Conclusion: The use of psychoactive drugs by mothers during pregnancy did not affect the NHS failure rate of this sample. However, the occurrence of significant risk factors in the study group showed a possible sensitivity of babies exposed to psychoactive drugs during pregnancy.



All right reserved. Prohibited the reproduction of papers
without previous authorization of FORL © 1997- 2024